Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 826 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Shelter Cat Who Battled Breast Cancer Seeks Fellow Survivor to Give... October 30, 2019 EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan November 14, 2022 ESMO Calls for Cancer Care Safeguards in the EU’s Health Crisis... November 11, 2025 Happy 29th Birthday OncoLink! March 7, 2023 Load more HOT NEWS Foster Teen With A Passion For Painting Is Patiently Waiting For... Gift Giving During a Pandemic Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App “Things Are Shrinking” Says Olivia Newton-John About Her Stage IV Breast...